Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 13,774 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: HIV Infections, AIDS-Related Opportunistic Infections
Interventions: Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 24 more

Conditions: Lung Cancer
Interventions: talabostat (PT-100) tablets, Docetaxel; Drug
Lead sponsor: Point Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Ocoee, Florida • Chicago, Illinois • Grosse Pointe Woods, Michigan + 7 more

Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Boca Raton, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Open Angle Glaucoma
Interventions: Suprachoroidal Dissection Instrument (SDI); Device
Lead sponsor: iScience Interventional Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer of Head and Neck
Interventions: wearable sensor; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hematuria - Cause Not Known
Interventions: Cxbladder Triage Plus; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more

Conditions: Esophagitis, Reflux, Esophagitis, Peptic
Interventions: Dexlansoprazole MR, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 100
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 43
States / cities: Andalusia, Alabama • Anniston, Alabama • Glendale, Arizona + 38 more

Conditions: Diabetes Mellitus, Type 2
Interventions: muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 108
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more

Conditions: Baseline Thrombocytopenia
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemophilic Arthropathy
Interventions: TRM-201 (Rofecoxib), Placebo; Drug
Lead sponsor: Tremeau Pharmceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 15 more

Conditions: Epilepsy
Interventions: USL261; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 12 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more

Conditions: Postoperative Pain
Interventions: Plain bupivacaine, Liposomal bupivacaine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 21 more

Conditions: Osteoporosis, Postmenopausal
Interventions: Blosozumab, Placebo; Biological · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas

Conditions: Alzheimer Disease
Interventions: Valproate, Placebo; Drug
Lead sponsor: Alzheimer's Disease Cooperative Study (ADCS); Other
Eligibility: 55 Years to 90 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 46
States / cities: Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more

Conditions: Insomnia
Interventions: PD 0200390, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 45
States / cities: Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more

Conditions: Short Gut Syndrome
Interventions: Green bean puree; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 4 Months to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Leukemia, Lymphoma
Interventions: biologic sample preservation procedure; Other
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 0 Years to 120 Years
Enrollment: 1,873 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 214
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 156 more

Conditions: Acute Decompensated Heart Failure
Interventions: Ularitide, Placebo; Drug
Lead sponsor: Cardiorentis; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Montgomery, Alabama • Sacramento, California + 34 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Posaconazole, Fluconazole; Drug
Lead sponsor: Schering-Plough; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Miami, Florida + 13 more

Conditions: Adult Male Hypogonadism
Interventions: Testosterone gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Huntsville, Alabama • Newport Beach, California • San Diego, California + 14 more

Conditions: HIV Infections
Interventions: Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 16 Years and older
Enrollment: 1,864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 30 more

Search by objective public record fields.

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Surgical Treatment of Refractory Open Angle Glaucoma

Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Valproate in Dementia (VALID)

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

Successful Fiber Food Introduction in Short Bowel Syndrome

Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults